Get started
Work

Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update

Year: 2016
Type: article
Study design: Clinical Trial
DOI: 10.1093/annonc/mdw383.15
Authors: F. Barlesi, M. Steins, L. Horn, N. Ready, E. Felip, H. Borghaei, D.R. Spigel, O. Arrieta, S.J. Antonia, J. Fayette, N. Rizvi, L. Crinò, M. Reck, W.E. Eberhardt, M. Hellmann, W.J. Geese, A. Li, D. Healey, J.R. Brahmer, L. Paz-Ares
Institutions: Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Duke Medical Center, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Fox Chase Cancer Center, Tennessee Oncology, Instituto Nacional de Cancerología, Moffitt Cancer Center, Centre Léon Bérard, Memorial Sloan Kettering Cancer Center, German Center for Lung Research, LungenClinic Grosshansdorf, Bristol-Myers Squibb (United States), Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Hospital Universitario 12 De Octubre
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2587999264
FWCI: 2.936
Cites:
Cited by: 22
Related to: 10